
































At first glance, growth and aging appear to be 
opposites.  Growth is energy-driven synthesis of 
macromolecules from simple nutrients, an increase of 
order and a decrease of entropy.  Aging is decay, a loss 
of order and a rise of entropy.  Seemingly, growth and 
aging are mutually exclusive.  Forever proliferating 
cells, such as legendary hydras, do not show signs of 
aging.  In contrast, when an organism ceases to grow, 
aging follows.  However, manipulations that decrease 
growth also decrease aging and prolong life span.  For 
example, calorie restriction (reduced nutrient intake) 
reduces growth and increases longevity in diverse 
species from yeast to mice.  Rapamycin, which inhibits 
growth in yeast, decelerates yeast aging.  Inactivation of 
the growth-promoting insulin/IGF-1 signaling pathway 
increases life span, from worms to mice.  Why do 
growth-inhibiting conditions slow down aging?  Are 
growth and aging mechanistically similar?  As we 
discuss here, growth and aging may not be opposites but 
rather a continuation of one another driven by the same 
molecular  pathway.   Aging  and  growth may  be linked 
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in a way that growth produces aging.  In other words, 
excessive growth is a driving force for aging.  The 
molecular pathway that drives both growth and aging 
appears to be the evolutionarily conserved TOR (target 
of rapamycin) pathway.  
 
The TOR pathway 
 
TOR (Target Of Rapamycin), as its name indicates, was 
originally discovered, in yeast, as the target of the 
antifungal drug rapamycin.  Rapamycin is a natural 
secondary metabolite produced by soil bacteria to 
inhibit growth of fungal competitors.  Thus, it is a 
mirror image of penicillin that is produced by fungi to 
inhibit bacterial growth.  Remarkably, TOR is struc-
turally and functionally conserved from yeast to human 
(including worms, flies, plants and mice) as an 
essential, central controller of cell growth [1]. TOR in 
mammals (mTOR) controls cell growth and metabolism 
in response to nutrients (e.g., amino acids), growth 
factors (e.g., insulin, IGF-1, PDGF), and cellular energy 
status (ATP).  Nutrients are the dominant TOR input as 
high levels of amino acids can compensate for an 
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[2], and only nutrients activate TOR in unicellular 
organisms.  The growth factor signaling pathway, 
grafted onto the more ancestral nutrient sensitive TOR 
pathway, co-evolved with multicellularity.  TOR 
activates cell growth by positively and negatively 
regulating several anabolic and catabolic processes, 
respectively, that collectively determine mass 
accumulation.  The anabolic processes include tran-
scription, protein synthesis, ribosome biogenesis, 
nutrient transport, and mitochondrial metabolism.   
Conversely, TOR negatively regulates catabolic 
processes such as mRNA degradation, ubiquitin-
dependent proteolysis, and autophagy.  TOR is an 
atypical serine/threonine kinase that is found in two 
functionally and structurally distinct multiprotein 
complexes, TORC1 and TORC2 (mTORC1 and 
mTORC2 in mammals), each of which signals via a 
different set of effector pathways.   TORC1 is rapamy-
cin sensitive whereas TORC2 is rapamycin insensitive.  
The best-characterized phosphorylation substrates of 
mTOR are S6K and 4E-BP1 via which mTORC1 
controls translation, and Akt/PKB via which mTORC2 
controls cell survival and other processes [3].  Like 
TOR itself, the two TOR complexes and the overall 
architecture of the TOR signaling network appear to be 
conserved from yeast to human [1, 4].  TOR and many 
of the processes it controls have also been shown to 
play a role in aging (in addition to growth) in a wide 
variety of organisms, as described below.      
 
Aging in budding yeast 
 
Budding yeast S. cerevisiae is a particularly useful 
model system to study aging because it can be used to 
study both replicative aging and chronological aging.   
Replicative aging is measured by the number of 
daughter cells (divisions) a mother cell can produce.   
Chronological aging, also referred to as postmitotic 
aging, is measured by the length of time a non-dividing 
cell can survive.  Inhibition of TORC1 signaling in 
yeast extends both replicative [5] and chronological [6] 
life span. Thus, TOR appears to promote aging 
regardless of physiological context (mitotic or post-
mitotic cells).   
 
In yeast, the link between growth and aging has been 
known since the 1950’s and is particularly spectacular. 
Yeast cells grow larger as they grow older [7, 8]. The 
yeast S. cerevisiae typically divides asymmetrically to 
give a large mother cell and a smaller daughter cell. As 
mother cells become old, they enlarge and produce 
daughter cells that are larger than daughters derived 
from young mother cells. Like large mothers, large 
daughter cells have shorter replicative life span [8].   
The use of unicellular yeast to study aging is revealing 
also because here the cell is the organism.  Therefore, it 
is a model for cell aging and organismal longevity.  As 
we discuss below, TOR also controls longevity in 
multicellular organisms. 
 
TOR and aging from worm to mammals  
 
Inhibition of TOR signaling enhances life span in 
worms, flies and possibly mammals.  The nematode C. 
elegans contains a constant number of post-mitotic cells 
and lives about twenty days.  The first demonstration 
that TOR controls life span was by Vellai et al [9] who 
showed that knocking down TOR in  -C. elegans more 
than doubles this worm's normal life span. They 
examined specifically the role of TOR in aging based 
on the prior knowledge that both TOR and life span are 
regulated by nutrients and insulin.  Indeed, a large body 
of earlier, groundbreaking work showing that calorie 
restriction [10, 11] or down regulation of insulin/IGF-1 
signaling [12, 13] extends life span is consistent with 
the observation that down regulation of TOR also 
extends life span.  Interestingly, inhibition of TOR 
starting either during development or on the first day of 
adulthood gives comparable life span extension, 
suggesting that TOR controls longevity mainly, if not 
exclusively, during adulthood [9].  Jia et al. [14] sub-
sequently demonstrated that worms deficient in raptor, a 
TORC1-specific subunit, also have an extended life 
span, indicating that TOR promotes aging via at least 
TORC1, if not via both TORCs. 
 
 In  Drosophila, TOR is required for growth during 
larval development, and for increases in cellular growth 
caused by growth factor signaling and nutrient 
availability [15]. Genetic inhibition of the Drosophila 
TOR pathway, either upstream or downstream of TOR, 
extends life span [16, 17].  Furthermore, reducing the 
function of Drosophila TOR results in decreased lipid 
stores and glucose levels, and prevents metabolic 
syndrome [18].  The life span extension is observed 
upon down regulation of TOR signaling in the fat body 
[17], underscoring the importance of fat in aging [19-
21, 12]. Downregulating TOR signaling in the fat body 
not only extends the life of the fly, it also reduces the 
size of the entire organism [22], providing yet another 
link between growth and aging. The apparently central 
role of TOR signaling in the fly fat body in regulating 
life span may be recapitulated by mammalian TOR in 
adipose tissue.  In mice, decreased insulin/IGF-1 sig-
naling in adipose tissue, and consequently less active 
downstream mTOR signaling, increases life span [23, 
20]. Furthermore, adult-onset growth hormone or IGF-1 
deficiency increases life span in rodents [24].  Also, 
mice deficient for mTORC1 or the mTORC1 effector 
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[25, 26]. Rapamycin is currently being tested for its 
ability to extend lifespan in mice in the National 
Interventions Testing Program. 
 
Finally, calorie restriction, in which nutrient intake is 
restricted to 60-70% that of voluntary levels, increases 
life span in most species including mammals [10-12]. 
Although anti-aging mechanisms of CR are still 
disputed, one of the mechanisms is likely inactivation of 
the TOR pathway. Indeed, taking into account that i) 
inhibition of TOR extends life span and ii) nutrients 
activate TOR, the mechanism of how restriction of 
nutrients can increase life span seems apparent.    
 
 Downstream of TOR 
 
How does TOR promote aging in response to nutrients?  
In other words, which of the many TORC1-controlled 
processes that are either up regulated or down regulated 
upon nutrient deprivation (TORC1 inactivation) leads to 
longer life?  Recent evidence suggests that TORC1 
controls aging via several of its downstream processes, 
including autophagy, ribosome biogenesis and protein 
synthesis, transcription, and mitochondrial activity.   
Indeed, there is a remarkable correlation between TOR-
controlled processes and processes in aging.  It is also 
important to note that these processes constitute the 
normal program via which TOR controls cell growth, 
suggesting that TOR control of aging is an extension or 
continuation of its control of growth.    
   
TORC1 inhibits autophagy, a process of bulk 
degradation of proteins and organelles by lysosomes 
[27].  Autophagy is inhibited in aging and age-related 
diseases [28]. Restoration of autophagy depletes 
mitochondria with deleterious mtDNA mutations but 
spares their normal counterparts [29]. Furthermore, 
autophagy is essential for life span extension at least in 
worms [30]. This suggests that TORC1 promotes aging 
in part via inhibition of autophagy. 
 
  TORC1 activates ribosome biogenesis and protein 
synthesis. Recent studies show that inhibition of 
ribosome biogenesis and global protein synthesis 
extends life span [31-34].  Reducing the levels of 
ribosomal proteins and translation initiation factors 
extends life span in both yeast and worms.  Thus, this is 
consistent with the notion that TORC1 may promote 
aging via activation of ribosome biogenesis and protein 
synthesis. 
 
TORC1 in yeast negatively regulates the stress-
activated transcription factors GIS1 and MSN2/4.  Both 
transcription factors are required for life span extension 
upon down regulation of TOR [35, 36]. A longevity-
related gene up regulated by MSN2/4 upon TOR 
inhibition is the nicotinamidase gene PCN1.  
Interestingly, nicotinamidase converts nicotinamide to 
NAD
+ which in turn activates SIR2, suggesting that 
TOR and sirtuins are part of the same longevity 
pathway [35].  Furthermore, as discussed below, TOR 
negatively regulates mitochondrial gene expression to 
limit life span [37]. 
 
TORC1 controls mitochondrial activity, but in different 
ways depending on the organism.  In yeast, TORC1 
inhibits mitochondrial respiration whereas in mammals 
(at least in muscle) it stimulates respiration [37-42].   
This divergence in regulation is probably related to the 
fact that glucose, a nutrient sensed by TORC1, triggers 
anaerobic fermentation in yeast.  A similar glucose-
dependent shift in respiration does not occur in 
mammals.  Consistent with the above, increased mito-
chondrial respiration extends life span in yeast whereas 
in mammalian cells life span extension correlates with 
reduced respiration [37, 39, 43].  However, the role of 
mitochondria in life span extension remains elusive, 
particularly with the recent demonstration that TORC1 
in mammalian adipose tissue, like in yeast, negatively 
controls respiration [26]. 
 
Accumulation of aggregation-prone proteins is involved 
in neurodegeneration. TOR causes neurodegeneration in 
a Drosophila tauopathy model [44]. The TOR pathway 
is involved in Alzheimer’s disease by increasing Tau 
protein synthesis [45].  Furthermore, rapamycin en-
hances clearance of pathologic proteins and thereby 
reduces their toxicity [46]. 
 
As we discuss below, overactive TOR seems to be 
involved in the hypertrophic phenotype of aging 
mammalian cells, thus linking TOR mediated cell 
hypertrophy to organismal aging. In contrast, a 
replicative limit has never been shown to be important 
in vivo [47]. It is a hyperthropic, secretory phenotype of 
aging cells that can be linked to organismal aging [48-
50]. 
 
Hypertrophic phenotype of aging cells 
 
If growth and aging are mechanistically linked, are 
older cells larger?  In yeast, old cells are large and cell 
size predicts replicative life span [51, 52]. This also 
appears to be the case for senescent mammalian cells.  
An increase in cell size is a hallmark of senescent 
fibroblasts [53]. Their cell volume is several fold 
greater compared with proliferating cells. Cell size is 
progressively increased in cell culture as cells progress 
toward senescence [54-56]. Furthermore, it was 
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senescence [54, 57]. Ironically, TOR had not been 
discovered at that time and the significance of this 
phenomenological observation was unclear. The notion 
that TOR is involved in both growth and aging now 
provides a mechanistic explanation for an old 
observation. 
 
Cell growth is an increase in cell volume, or mass, due 
to metabolic activity including synthesis of 
macromolecules (RNA, protein, lipid) and organelles.   
If a cell grows without division, it becomes hyper-
trophic.  In other words, when the cell cycle is blocked 
in the presence of growth-promoting signaling, then 
cells increase in size [56, 58, 59].   
 
Thus, cell growth is counterbalanced by cell division 
such that cells maintain a characteristic size.  The 
simplest way to cause both cell hypertrophy and cell 
senescence is to prevent cell division without inhibiting 
cell growth. Inhibition of mTOR with rapamycin 
decreases the hypertrophic cell phenotype caused by 
induction of the CDK inhibitor p21 [58-60].    
 
All these observations suggest that mTOR signaling 
plays a role in aging of single cells.  How is this related 
to aging of multicellular organisms?  As discussed else-
where [1, 61], TOR-driven alterations can be linked to 
metazoan aging and, in particular, diseases of aging 
such as cancer, metabolic syndrome, atherosclerosis, 
hypertension and hypertrophic heart.  
 
Rapamycin in humans 
 
Rapamycin is given to renal transplant patients 
everyday for several years to prevent organ rejection.  
We view this as an unintentional clinical trial of a 
potentially anti-aging drug. First, in such patients, 
rapamycin unexpectedly turned out to prevent cancer 
[62-64] and even cured some types of pre-existing 
tumors [65, 66]. Second, 2 years after transplantation, 
body-mass index was significantly lower in the 
rapamycin-based treatment arm compared to 
cyclosporine, indicating that rapamycin prevents obesity 
[67].  
 
Rapamycin is safe enough to be used in healthy 
volunteers to study its pharmacokinetics [68-70].  In 
healthy volunteers, a single dose was not associated 
with side effects. In 11 healthy men (29 years old, BMI 
23 kg/m
2), 6 mg of rapamycin decreased S6K phospho-
rylation, preventing insulin resistance caused by 
nutrients. Thus, the activity state of the mTOR pathway 
can modulate insulin sensitivity in humans and mTOR 
inhibitors prevent nutrient-induced insulin resistance 
[70]. 
 
  Why TOR?  
 
Cell growth and division are the two most fundamental 
features of life. Using simple compounds and energy, 
living organisms build macromolecules according to 
their own plan, transforming non-self to self.  Not 
surprisingly, the growth-controlling TOR signaling 
pathway is conserved from yeast to human.  In 
unicellular organisms, it maximizes growth as long as 
nutrients are available.  However, life-promoting TOR 
signaling seems also to contain seeds of death.  Aging 
and its manifestations such as age-related diseases 
appear with excessive growth-promoting signaling, 
when actual growth is not longer possible. Aging is not 
programmed, of course, but is an aimless continuation 
of the same process that drives developmental growth. 
Since aging does not limit life span in the wild, switch-
off of this ‘growth program’ cannot evolve.  Growth 
should be robust and not be slowed down to avoid 
aging. Furthermore, the aging-growth program cannot 
be switched off by an accidental mutation, because such 
a mutation would be lethal or at least reduce fitness 
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